CHRONIC MYELOGENOUS LEUKEMIA - A REVIEW OF PATHOPHYSIOLOGY, CLINICO-LABORATORY FEATURES AND EMERGING TREATMENT OPTIONS

Dr Nwagu Marcellinus Uchechukwu and AWODU OA, NWANADI   (Published 2018)

Dr Marcellinus Uchechukwu
See Profile Page

Abstract

Summary
Chronic Myelogenous Leukemia (CML) is a myeloproliferative disorder.
characterized by the presence of Philadelphia chromosome and affects a good number of
Africans and African-American population. The aim of this review is to highlight the
aetiophysiology, clinical/laboratory characteristics and treatment options, especially the new
and emerging treatment modalities of CML. The review was sourced mainly from internet
(pubmed). Relevant Oncology journals and textbooks of haematology were also consulted.
There are reported cases of relapse/resistance to imatinib which is the current drug of choice in
CML treatment. Research has reached advanced stage on the use of qlternative drugs (eg
Nilotinib and Desatinib) especially in resistant cases. It is hoped that these new drugs will
become the treatment of choice and first line drugs for the treatment of C;ML. We recommend
that these new drugs should also be made available and free (just like Imatinib) to resourcepoor
African countries like Nigeria.


Item Type: Journal article(non-copyrighted)
Format: PDF document,   3.61 MB
Copyright: Creative Commons LicenseCreative Commons license
Keywords: medicine
Department: Medicine and Surgery
Field of Study: Medicine
Uploaded By: Uwaifo Ferdinand
Date Added: 15 Mar 2019 2:28pm
Last Modified: 15 Mar 2019
Journal URL: https://www.edouniversity.edu.ng/oer/journal/chronic_myelogenous_leukemia_-_a_review_of_pathophysiology_clinico-laboratory_features_and_emerging_treatment_options


Google Docs     Print     Download

If you love watching movies on your android phone, download moviebox pro apk for free

The MyCCPay has a super advanced Bank Statements with Program Fee for Visa on our Home Page to effortlessly increase Funds having Social Security number that get Customer Support Team from the United States before seeing Transaction History and their extra Benefits into Current Balance.